summary
Introduced
05/09/2019
05/09/2019
In Committee
05/09/2019
05/09/2019
Crossed Over
Passed
Dead
12/31/2020
12/31/2020
Introduced Session
116th Congress
Bill Summary
Requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.
AI Summary
This bill, the Fair Accountability and Innovative Research Drug Pricing Act of 2019, requires drug manufacturers to report certain price increases for prescription drugs and biological products that cost at least $100 per month. The reports must include the percentage price increase, a justification for the increase, the drug's price history, the total cost to develop the drug, and the total revenue and net profit generated from the drug. The bill also establishes civil penalties for manufacturers that fail to submit these required reports and requires the Secretary of Health and Human Services to publicly post the reports, while protecting trade secrets and confidential information.
Committee Categories
Health and Social Services
Sponsors (8)
Tammy Baldwin (D)*,
Mike Braun (R),
Sherrod Brown (D),
Kevin Cramer (R),
John Hoeven (R),
Angus King (I),
Lisa Murkowski (R),
Tina Smith (D),
Last Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 05/09/2019)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/116th-congress/senate-bill/1391/all-info |
| BillText | https://www.congress.gov/116/bills/s1391/BILLS-116s1391is.pdf |
| Bill | https://www.congress.gov/116/bills/s1391/BILLS-116s1391is.pdf.pdf |
Loading...